97 related articles for article (PubMed ID: 10419880)
1. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses.
Rook AH; Wood GS; Yoo EK; Elenitsas R; Kao DM; Sherman ML; Witmer WK; Rockwell KA; Shane RB; Lessin SR; Vonderheid EC
Blood; 1999 Aug; 94(3):902-8. PubMed ID: 10419880
[TBL] [Abstract][Full Text] [Related]
2.
Blümel E; Munir Ahmad S; Nastasi C; Willerslev-Olsen A; Gluud M; Fredholm S; Hu T; Surewaard BGJ; Lindahl LM; Fogh H; Koralov SB; Rahbek Gjerdrum LM; Clark RA; Iversen L; Krejsgaard T; Bonefeld CM; Geisler C; Becker JC; Woetmann A; Andersen MH; Buus TB; Ødum N
Oncoimmunology; 2020; 9(1):1751561. PubMed ID: 32363124
[No Abstract] [Full Text] [Related]
3. Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia.
Sheikh V; Porter BO; DerSimonian R; Kovacs SB; Thompson WL; Perez-Diez A; Freeman AF; Roby G; Mican J; Pau A; Rupert A; Adelsberger J; Higgins J; Bourgeois JS; Jensen SM; Morcock DR; Burbelo PD; Osnos L; Maric I; Natarajan V; Croughs T; Yao MD; Estes JD; Sereti I
Blood; 2016 Feb; 127(8):977-88. PubMed ID: 26675348
[TBL] [Abstract][Full Text] [Related]
4. The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma.
Rook AH; Kubin M; Fox FE; Niu Z; Cassin M; Vowels BR; Gottleib SL; Vonderheid EC; Lessin SR; Trinchieri G
Ann N Y Acad Sci; 1996 Oct; 795():310-8. PubMed ID: 8958942
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.
Rudman SM; Jameson MB; McKeage MJ; Savage P; Jodrell DI; Harries M; Acton G; Erlandsson F; Spicer JF
Clin Cancer Res; 2011 Apr; 17(7):1998-2005. PubMed ID: 21447719
[TBL] [Abstract][Full Text] [Related]
6. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.
Duvic M; Sherman ML; Wood GS; Kuzel TM; Olsen E; Foss F; Laliberté RJ; Ryan JL; Zonno K; Rook AH
J Am Acad Dermatol; 2006 Nov; 55(5):807-13. PubMed ID: 17052486
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
Younes A; Pro B; Robertson MJ; Flinn IW; Romaguera JE; Hagemeister F; Dang NH; Fiumara P; Loyer EM; Cabanillas FF; McLaughlin PW; Rodriguez MA; Samaniego F
Clin Cancer Res; 2004 Aug; 10(16):5432-8. PubMed ID: 15328181
[TBL] [Abstract][Full Text] [Related]
8. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.
Leonard JP; Sherman ML; Fisher GL; Buchanan LJ; Larsen G; Atkins MB; Sosman JA; Dutcher JP; Vogelzang NJ; Ryan JL
Blood; 1997 Oct; 90(7):2541-8. PubMed ID: 9326219
[TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Schwartz LH; Olencki T; Malone TM; Sandstrom K; Nadeau R; Parmar H; Bukowski R
Clin Cancer Res; 1998 May; 4(5):1183-91. PubMed ID: 9607576
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma.
Bajetta E; Del Vecchio M; Mortarini R; Nadeau R; Rakhit A; Rimassa L; Fowst C; Borri A; Anichini A; Parmiani G
Clin Cancer Res; 1998 Jan; 4(1):75-85. PubMed ID: 9516955
[TBL] [Abstract][Full Text] [Related]
12. IL-12 family cytokines: immunological playmakers.
Vignali DA; Kuchroo VK
Nat Immunol; 2012 Jul; 13(8):722-8. PubMed ID: 22814351
[TBL] [Abstract][Full Text] [Related]
13. A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors.
Rotta G; Gilardoni E; Ravazza D; Mock J; Seehusen F; Elsayed A; Puca E; De Luca R; Pellegrino C; Look T; Weiss T; Manz MG; Halin C; Neri D; Dakhel Plaza S
EMBO Mol Med; 2024 Apr; 16(4):904-926. PubMed ID: 38448543
[TBL] [Abstract][Full Text] [Related]
14. Generation and
Plüss L; Peissert F; Elsayed A; Rotta G; Römer J; Dakhel Plaza S; Villa A; Puca E; De Luca R; Oxenius A; Neri D
MAbs; 2023; 15(1):2217964. PubMed ID: 37243574
[TBL] [Abstract][Full Text] [Related]
15. Advances in the understanding and treatment of Cutaneous T-cell Lymphoma.
Bakr FS; Whittaker SJ
Front Oncol; 2022; 12():1043254. PubMed ID: 36505788
[TBL] [Abstract][Full Text] [Related]
16. IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines.
Jia Z; Ragoonanan D; Mahadeo KM; Gill J; Gorlick R; Shpal E; Li S
Front Immunol; 2022; 13():952231. PubMed ID: 36203573
[TBL] [Abstract][Full Text] [Related]
17. Generation and
Nadal L; Peissert F; Elsayed A; Weiss T; Look T; Weller M; Piro G; Carbone C; Tortora G; Matasci M; Favalli N; Corbellari R; Di Nitto C; Prodi E; Libbra C; Galeazzi S; Carotenuto C; Halin C; Puca E; Neri D; De Luca R
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104101
[TBL] [Abstract][Full Text] [Related]
18. Analysis of potential biomarkers of response to IL-12 therapy.
Schwarz E; Carson WE
J Leukoc Biol; 2022 Sep; 112(3):557-567. PubMed ID: 35790025
[TBL] [Abstract][Full Text] [Related]
19. Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives.
Atallah-Yunes SA; Robertson MJ
Front Immunol; 2022; 13():872010. PubMed ID: 35529882
[TBL] [Abstract][Full Text] [Related]
20. Harnessing cytokines and chemokines for cancer therapy.
Propper DJ; Balkwill FR
Nat Rev Clin Oncol; 2022 Apr; 19(4):237-253. PubMed ID: 34997230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
